I agree with You Weaver.

For the investors it depends on the global success of the company with their products. The Covid opportunity if not able to be capitalize on the situation here just means we didn't have a product to service the sector in the good ol' USA.
We were a struggling company with an innovative product in addition to the base test stripe market. We will still be at minimum that same company in say 6 months to a year. Genviro is frosting on the cake.

For others here and elsewhere that are fooling nobody but them selves, it's not about the company. Its personal and the company is just a vehicle to that nefarious end.

Just my opine from observations made here and elsewhere.

Have a nice day.

:}